Table 1 Baseline characteristics
Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|
surgery group (n = 251, %) | PORT group (n = 255, %) | p value | Surgery group (n = 157, %) | PORT group (n = 157, %) | p value | ||
Gender | 0.94 | 0.36 | |||||
Male | 222 (88.4) | 225 (88.2) | 84 (53.5) | 138 (87.9) | |||
Female | 29 (11.6) | 30 (11.8) | 73 (46.5) | 19 (12.1) | |||
Age | 0.43 | 0.17 | |||||
≤ 60 | 132 (52.6) | 143 (56.1) | 84 (53.5) | 96 (61.1) | |||
> 60 | 119 (47.4) | 112 (43.9) | 73 (46.5) | 61 (38.9) | |||
Differentiation | 0.43 | 0.56 | |||||
Well | 16 (6.4) | 22 (8.6) | 9 (5.7) | 9 (5.7) | |||
Moderate | 135 (53.8) | 143 (56.1) | 89 (56.7) | 98 (62.4) | |||
Poor | 100 (39.8) | 90 (35.3) | 59 (37.6) | 50 (31.8) | |||
Dissection field | < 0.001 | 0.19 | |||||
Three field | 53 (21.1) | 15 (5.9) | 19 (12.1) | 12 (7.6) | |||
Two field | 198 (78.9) | 239 (94.1) | 138 (87.9) | 145 (92.4) | |||
Tumor location | < 0.001 | 0.58 | |||||
Upper TEC | 21 (8.4) | 16 (6.3) | 5 (3.2) | 8 (5.1) | |||
Middle TEC | 133 (53.0) | 84 (32.9) | 63 (40.1) | 67 (42.7) | |||
Lower TEC | 97 (38.6) | 155 (60.8) | 89 (56.7) | 82 (52.2) | |||
Dissection LN | < 0.001 | 0.65 | |||||
≤ 21 | 158 (62.9) | 109 (42.7) | 82 (52.2) | 78 (49.7) | |||
> 21 | 93 (37.1) | 146 (57.3) | 75 (47.8) | 79 (50.3) | |||
T stage | 0.39 | 0.24 | |||||
T3 | 236 (94.0) | 244 (95.7) | 153 (97.5) | 149 (94.9) | |||
T4 | 15 (6.0) | 11 (4.3) | 4 (2.5) | 8 (5.1) | |||
N stage | < 0.001 | 1.00 | |||||
N0-1 | 231 (92.0) | 175 (68.6) | 139 (88.5) | 139 (88.5) | |||
N2-3 | 20 (8.0) | 80 (31.4) | 18 (11.5) | 18 (11.5) | |||
Chemotherapy | 0.01 | 0.65 | |||||
No | 138 (55.0) | 111 (43.5) | 82 (52.2) | 78 (49.7) | |||
Yes | 113 (45.0) | 144 (56.5) | 75 (47.8) | 79 (50.3) | |||